Organogenesis Cuts Revenue Forecast After Third-Quarter Sales Fall 70%
Management expects a slower fourth-quarter recovery, while cash and restricted cash stood at $26.9 million at September 30.
Organogenesis, which makes regenerative medicine products for wound care and surgery, cut its 2026 revenue forecast Thursday after third-quarter product sales fell 70% to $45.5 million. The company expects fourth-quarter sales to improve from the previous quarter, but more slowly than its earlier forecast assumed, according to the earnings release furnished with its SEC filing.
A Slower Fourth-Quarter Recovery
The revised outlook puts annual revenue at $179.4 million to $200.0 million, down 65% to 68% from 2025 revenue of $564.2 million. Management now expects second-half sales to decline approximately 68% to 74% from a year earlier; its previous forecast called for a 64% to 74% decline.
President, CEO and board chair Gary S. Gillheeney, Sr. pointed to progress against the preceding quarter: “Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio.” The annual comparison remained much weaker: third-quarter product sales were $105.0 million below the year-earlier $150.5 million.
Wound Care Drives The Decline
Wound-care sales accounted for $103.3 million of the decline. Revenue from those products fell 73% to $38.2 million, while surgical and sports-medicine sales dropped 19% to $7.3 million.
Organogenesis sells products including Apligraf, a bioengineered skin substitute used for venous leg ulcers and diabetic foot ulcers, PuraPly collagen wound matrices, and placental tissue grafts NuShield and Affinity. Customers include hospitals, wound-care centers, government facilities, ambulatory surgery centers and physician offices; substantially all sales are in the United States.
The contraction extends beyond the quarter. Product revenue for the first nine months totaled $124.5 million, down 63% from $338.0 million a year earlier. Wound-care revenue fell 67% over that period.
Lower Costs, But A Quarterly Loss
Gross profit—the money remaining after product costs—was $23.6 million, compared with $114.2 million a year earlier. That left a gross margin of 52%, versus 76%.
Operating expenses fell 42% to $74.9 million from $130.1 million. Product costs declined 40% to $21.9 million, selling and administrative expenses fell 43% to $45.1 million, and research and development spending dropped 40% to $8.0 million.
Those reductions did not preserve profitability. The operating result moved from a $20.7 million profit to a $29.5 million loss. Net loss was $29.6 million, or $0.25 per share, against year-earlier earnings of $21.6 million, or $0.11 per share. On an adjusted basis, the company lost $29.3 million, compared with a $23.2 million profit.
Cash, cash equivalents and restricted cash totaled $26.9 million at September 30, versus $94.3 million at December 31, 2025. Organogenesis reported no outstanding debt obligations at either date.
Operations used $29.120 million in cash during the first nine months, compared with $49.729 million a year earlier—a smaller cash outflow even as sales contracted.
Sources
- 8-K Filing — Organogenesis Holdings Inc. (ORGO) — SEC EDGAR
- Exhibit orgo-ex99_1.htm — Organogenesis Holdings Inc. 8-K exhibit — SEC EDGAR
- Organogenesis (ORGO) Q3 2026 Earnings Call Transcript - The Globe and Mail — theglobeandmail.com
- Organogenesis Holdings Inc. Reports Third Quarter 2026 — globenewswire.com